Bulletin
Investor Alert

New York Markets Open in:

Roche Holding AG Part. Cert.

OTC: RHHVF

GO
/marketstate/country/us

Market closed

 --Quotes are delayed by 20 min

Jan 27, 2022, 3:42 p.m.

/zigman2/quotes/206948568/composite

$

379.51

Change

+6.16 +1.65%

Volume

Volume 3,948

Quotes are delayed by 20 min

/zigman2/quotes/206948568/composite

Previous close

$ 373.35

$ 379.51

Change

+6.16 +1.65%

Day low

Day high

$375.50

$382.14

Open

52 week low

52 week high

$308.57

$420.00

Open

Company Description

Roche Holding AG operates as a research healthcare company. It operates through the following divisions: Pharmaceuticals and Diagnostics. The Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four busin...

Roche Holding AG operates as a research healthcare company. It operates through the following divisions: Pharmaceuticals and Diagnostics. The Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized & point of care solutions, molecular diagnostics, tissue diagnostics & diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Valuation

P/E Current

21.13

P/E Ratio (with extraordinary items)

21.47

P/E Ratio (without extraordinary items)

18.48

Price to Sales Ratio

4.58

Price to Book Ratio

7.25

Price to Cash Flow Ratio

14.72

Enterprise Value to EBITDA

13.51

Enterprise Value to Sales

5.04

Total Debt to Enterprise Value

0.06

Efficiency

Revenue/Employee

574,809.00

Income Per Employee

140,886.00

Receivables Turnover

4.88

Total Asset Turnover

0.69

Liquidity

Current Ratio

1.30

Quick Ratio

1.01

Cash Ratio

0.49

Profitability

Gross Margin

71.96

Operating Margin

30.40

Pretax Margin

30.80

Net Margin

24.51

Return on Assets

16.89

Return on Equity

41.38

Return on Total Capital

33.25

Return on Invested Capital

30.50

Capital Structure

Total Debt to Total Equity

42.41

Total Debt to Total Capital

29.78

Total Debt to Total Assets

17.89

Long-Term Debt to Equity

30.53

Long-Term Debt to Total Capital

21.44

Officers and Executives

Name Age Officer Since Title
Dr. Severin Schwan 53 2008 Chief Executive Officer
Dr. Alan Hippe 69 2011 Chief Financial Officer
Dr. Gallia G. Levy - - Associate Group Medical Director-Hematology
Ms. Pascale Schmidt 47 2020 Chief Compliance Officer
Dr. William Pao 52 2014 Global Head-Oncology Disease & Translational Area

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
12/16/2021 Executive Officer Swiss
19,920   Disposition at $379.95 per share. 7,568,627
12/16/2021 Executive Officer Swiss
19,920   Derivative/Non-derivative trans. at $379.95 per share. 7,568,627
08/12/2021 Executive Officer Swiss
3,163   Disposition at $368.23 per share. 1,164,698
08/09/2021 Executive Officer Swiss
8,788   Acquisition at $362.2 per share. 3,183,013
08/09/2021 DIRECTOR Swiss Non EXECUTIVE
271   Acquisition at $394.4 per share. 106,881
07/30/2021 Executive Officer Swiss
4,317   Disposition at $350 per share. 1,510,950
07/30/2021 Executive Officer Swiss
1,116   Disposition at $350 per share. 390,600
06/22/2021 Executive Officer Swiss
500   Disposition at $374.8 per share. 187,400
06/17/2021 Executive Officer Swiss
3,000   Disposition at $348.6 per share. 1,045,800
06/17/2021 Executive Officer Swiss
2,000   Disposition at $373.13 per share. 746,250
06/11/2021 Executive Officer Swiss
500   Disposition at $366 per share. 183,000
06/08/2021 Executive Officer Swiss
4,057   Disposition at $329.94 per share. 1,338,580
05/11/2021 Executive Officer Swiss
1   Award at $0 per share. 0
05/11/2021 Executive Officer Swiss
1   Acquisition at $499,995 per share. 499,995
05/11/2021 Executive Officer Swiss
1   Acquisition at $137,490 per share. 137,490
05/11/2021 Executive Officer Swiss
1   Acquisition at $93,720 per share. 93,720
03/23/2021 Executive Officer Swiss
1,189   Disposition at $310 per share. 368,590
03/23/2021 Executive Officer Swiss
1,810   Disposition at $310 per share. 561,100
/news/latest/company/us/rhhvf

MarketWatch News on RHHVF

  1. Merck & Co. Inc. stock outperforms market on strong trading day

    5:10 p.m. Jan. 27, 2022

    - MarketWatch Automation

  2. Eli Lilly & Co. stock outperforms market despite losses on the day

    5:06 p.m. Jan. 27, 2022

    - MarketWatch Automation

  3. Amgen Inc. stock outperforms market on strong trading day

    4:36 p.m. Jan. 27, 2022

    - MarketWatch Automation

  4. Abbott Laboratories stock rises Thursday, outperforms market

    4:33 p.m. Jan. 27, 2022

    - MarketWatch Automation

  5. Merck & Co. Inc. stock falls Wednesday, underperforms market

    5:10 p.m. Jan. 26, 2022

    - MarketWatch Automation

  6. Eli Lilly & Co. stock falls Wednesday, underperforms market

    5:06 p.m. Jan. 26, 2022

    - MarketWatch Automation

  7. Amgen Inc. stock underperforms Wednesday when compared to competitors

    4:36 p.m. Jan. 26, 2022

    - MarketWatch Automation

  8. Eli Lilly & Co. stock falls Tuesday, still outperforms market

    5:06 p.m. Jan. 25, 2022

    - MarketWatch Automation

  9. Amgen Inc. stock outperforms market despite losses on the day

    4:36 p.m. Jan. 25, 2022

    - MarketWatch Automation

  10. Abbott Laboratories stock falls Tuesday, still outperforms market

    4:33 p.m. Jan. 25, 2022

    - MarketWatch Automation

  11. Merck & Co. Inc. stock underperforms Monday when compared to competitors

    5:10 p.m. Jan. 24, 2022

    - MarketWatch Automation

  12. Eli Lilly & Co. stock falls Monday, underperforms market

    5:06 p.m. Jan. 24, 2022

    - MarketWatch Automation

  13. Amgen Inc. stock falls Monday, underperforms market

    4:36 p.m. Jan. 24, 2022

    - MarketWatch Automation

  14. Abbott Laboratories stock underperforms Monday when compared to competitors

    4:33 p.m. Jan. 24, 2022

    - MarketWatch Automation

  15. Merck & Co. Inc. stock underperforms Friday when compared to competitors

    5:10 p.m. Jan. 21, 2022

    - MarketWatch Automation

  16. Eli Lilly & Co. stock outperforms competitors despite losses on the day

    5:06 p.m. Jan. 21, 2022

    - MarketWatch Automation

  17. Amgen Inc. stock outperforms market despite losses on the day

    4:36 p.m. Jan. 21, 2022

    - MarketWatch Automation

  18. Abbott Laboratories stock outperforms competitors on strong trading day

    4:33 p.m. Jan. 21, 2022

    - MarketWatch Automation

  19. Loading more headlines...
/news/nonmarketwatch/company/us/rhhvf

Other News on RHHVF

  1. IXJ: Healthcare Dashboard For December

    4:07 a.m. Dec. 17, 2021

    - Seeking Alpha

  2. Wide-Moat Stocks On Sale - The December 2021 Heat Map

    6:28 a.m. Nov. 26, 2021

    - Seeking Alpha

  3. VYMI: International High Yield Overweight In Financials

    1:35 a.m. Nov. 6, 2021

    - Seeking Alpha

  4. Biogen: The Price Is Wrong

    7:00 a.m. Oct. 8, 2021

    - Seeking Alpha

  5. Roche Holding (RHHBY) Investor Presentation - Slideshow

    2:43 p.m. Sept. 17, 2021

    - Seeking Alpha

  6. Wide-Moat Stocks On Sale - The September 2021 Heat Map

    7:48 a.m. Sept. 1, 2021

    - Seeking Alpha

  7. Tracking Tweedy Browne Portfolio - Q2 2021 Update

    11:46 p.m. Aug. 19, 2021

    - Seeking Alpha

  8. Wide-Moat Stocks On Sale - The August 2021 Heat Map

    9:48 a.m. July 25, 2021

    - Seeking Alpha

  9. Roche Holding AG 2021 Q2 - Results - Earnings Call Presentation

    9:36 a.m. July 22, 2021

    - Seeking Alpha

  10. BioLineRx: A Top Candidate For A Takeover Before 2022 Ends

    3:12 p.m. June 30, 2021

    - Seeking Alpha

  11. Wide-Moat Stocks On Sale - The July 2021 Heat Map

    6:18 a.m. June 25, 2021

    - Seeking Alpha

  12. Loading more headlines...

At a Glance

Roche Holding AG

Grenzacherstrasse 124

Basel, Basel-Stadt (Basle Town) 4070

Phone

41 616881111

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$58.32B

Net Income

$14.30B

Employees

101,465

/news/pressrelease/company/us/rhhvf

Press Releases on RHHVF

No News currently available for RHHVF

Trending Tickers
  • /zigman2/quotes/202561856/composite MSTR-17.84%
  • /zigman2/quotes/205315244/composite DHT-4.09%
X
Powered by StockTwits
Link to MarketWatch's Slice.